Summary
This prediction ended on 04.11.19 with a price of -. stratec's BUY prediction for Zymeworks closed unchanged from the start price. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Zymeworks | - | - | - | - |
| iShares Core DAX® | -0.168% | 4.802% | 17.488% | 17.061% |
| iShares Nasdaq 100 | 2.946% | 3.520% | 23.619% | 36.065% |
| iShares Nikkei 225® | 1.319% | 6.746% | 12.949% | 0.580% |
| iShares S&P 500 | 2.044% | 3.551% | 23.055% | 39.407% |
Comments by stratec for this prediction
In the thread Zymeworks diskutieren
Zymeworks possesses multiple therapeutic platforms that could create more value in 2018.
The opportunity to take a position here appears especially appropriate for readers who have a more conservative risk tolerance profile, preferring situations with limited downside and significant upside potential. The company possesses multiple therapeutic platforms which have received validation as seen in current active partnerships.
Es gibt keinen Handelsplatz